Synthomer (SYNT) AI Stock Analysis

• Market Cap: £81.78M
• Dividend Yield: N/A
• Average Volume (3M): 1.10M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.64
• Revenue Growth: -4.41%
• EPS Growth: 2.29%
• Country: UK
• Employees: 4,000
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): N/A
• Shares Outstanding: 163,567,630
• 10 Day Avg. Volume: 933,327
• 30 Day Avg. Volume: 1,097,050
• PEG Ratio: 0.08
• Price to Book (P/B): 0.24
• Price to Sales (P/S): 0.13
• P/FCF Ratio: -2.12
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £74.67
• Price Target Upside: 59.72% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Neutral
• Price Target: 54.00p ▲(15.51% Upside)

Synthomer's overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. The company's negative earnings and lack of dividend yield further weigh down its valuation. Without significant improvements in profitability and market sentiment, the stock remains a high-risk investment.

Positive Factors

Innovation and Sustainability

Synthomer's focus on innovation and sustainability positions it well to meet customer demands and maintain a competitive edge in the specialty chemicals market.

Strategic Partnerships

Strategic partnerships expand Synthomer's market reach and diversify its product offerings, strengthening its position in various industries and supporting long-term growth.

Diverse Revenue Streams

Synthomer's diverse revenue streams across multiple sectors provide resilience against market fluctuations and support stable long-term financial performance.

Negative Factors

High Debt Levels

High leverage increases financial risk and limits flexibility, potentially impacting Synthomer's ability to invest in growth opportunities and manage economic downturns.

Negative Cash Flow

Negative cash flow indicates inefficiencies in operations and may hinder Synthomer's ability to fund new projects, pay down debt, or return capital to shareholders.

Declining Profitability

Declining profitability suggests operational challenges and competitive pressures, which could affect Synthomer's ability to sustain margins and invest in future growth.

Synthomer Business Overview & Revenue Model

Company Description

Synthomer plc operates as a specialty chemicals company. It operates through four segments: Performance Elastomers, Functional Solutions, Industrial Specialities, and Acrylate Monomers. The company offers pressure sensitive adhesives, acrylic polymers, acrylic dispersions, saturants, release coatings, and other adhesives; water-based carboxylated styrene butadiene rubber, redispersible powder, flooring adhesive, and additives for construction applications; and impregnation binders, styrene butadiene copolymers, dispersions, polymer binders, and butadiene-based binders for textiles applications. It also provides binders for various carpets; synthetic binders for graphic, packaging, and specialty paper coating applications; paper coating additives and plastic pigments; binders, dispersions, water-based and solvent-borne resins, and other products for various coating applications; foamed bedding products and footwear; elastomeric modifiers for thermoplastics and friction components; reinforcement resins for rubber compounds; and latex for tire cord. In addition, the company offers compounds and aqueous curing pastes for carpets and other applications; acrylic monomers for enhancing the performance characteristics of polymer formulations; antioxidant products; latices for medical examination, clean room, food handling, chemotherapy drug handling, chemical laboratory, and medical device and balloon applications; and nitrile latex, which enhance performance of industrial and fabric-supported gloves. Further, it provides liquid polybutadienes, polyvinyl alcohol suspending agents, polyvinyl acetates, thermosetting resins, butyl ethyl propanediol, and inorganic materials for various industrial applications; and coalescing agents for enhancing the properties of coatings. The company was formerly known as Yule Catto & Co. plc and changed its name to Synthomer plc in 2012. Synthomer plc was founded in 1863 and is headquartered in London, the United Kingdom.

How the Company Makes Money

Synthomer generates revenue primarily through the sale of its specialty chemical products, particularly aqueous polymers, which are used in a wide range of applications across diverse industries. The company operates on a B2B revenue model, supplying its products to manufacturers in sectors like construction, automotive, and consumer goods. Key revenue streams include sales of adhesives, paints, coatings, and construction materials. Additionally, Synthomer's strategic partnerships with various industrial players enhance its market reach and product offerings. The company's focus on innovation, alongside its commitment to sustainability, positions it favorably in the market, allowing it to charge premium prices for its specialized products while also reducing costs through efficient manufacturing processes. Global economic trends, regulatory changes, and advances in technology also play significant roles in influencing Synthomer's financial performance.

Synthomer Financial Statement Overview

Summary

Synthomer faces financial challenges across income, balance sheet, and cash flow verticals. The company is struggling with profitability and cash generation, while maintaining a high debt level. Addressing these issues will be crucial for improving its financial stability and growth prospects in the future.

Income Statement

Synthomer's income statement shows a challenging financial position with declining profitability. The gross profit margin has deteriorated significantly from previous years, and both EBIT and net income are in negative territory, indicating operational struggles. The revenue growth rate is relatively flat, demonstrating a lack of top-line growth. The company needs to address these issues to improve its financial health.

Balance Sheet

The balance sheet reflects a moderate financial position with high leverage. The debt-to-equity ratio has increased, indicating rising financial risk. Return on equity is negative due to net losses, which is concerning. However, the equity ratio remains above 40%, showing some level of financial stability. Synthomer needs to manage its liabilities and improve profitability to enhance its balance sheet strength.

Cash Flow

The cash flow statement reveals significant pressure, with negative free cash flow and operating cash flow in the latest period. The free cash flow growth rate is negative, showing a decline in cash generation. Additionally, the operating cash flow to net income ratio is unfavorable, suggesting inefficiencies in converting income to cash. Synthomer must improve its cash flow management to ensure long-term sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.86B	1.99B	1.97B	2.33B	2.14B	1.64B
Gross Profit	336.90M	337.70M	307.30M	281.00M	569.70M	336.70M
EBITDA	70.30M	83.00M	113.40M	139.40M	394.40M	146.90M
Net Income	-83.60M	-72.60M	-67.00M	-32.50M	208.70M	3.10M
Balance Sheet
Total Assets	2.45B	2.54B	2.71B	3.15B	2.55B	2.13B
Cash, Cash Equivalents and Short-Term Investments	266.40M	225.80M	371.30M	227.70M	505.30M	201.80M
Total Debt	960.60M	878.70M	926.30M	1.30B	663.00M	719.00M
Total Liabilities	1.46B	1.43B	1.54B	2.11B	1.52B	1.50B
Stockholders Equity	983.70M	1.09B	1.15B	1.02B	1.02B	615.00M
Cash Flow
Free Cash Flow	-82.70M	-124.10M	66.00M	45.00M	193.20M	134.90M
Operating Cash Flow	14.90M	-33.50M	150.00M	135.80M	275.40M	188.70M
Investing Cash Flow	-70.60M	-61.70M	107.70M	-850.10M	-78.60M	-365.80M
Financing Cash Flow	44.80M	-45.90M	-90.90M	414.50M	118.50M	273.20M

Synthomer Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 46.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SYNT, the sentiment is Negative. The current price of 46.75 is below the 20-day moving average (MA) of 56.90, below the 50-day MA of 62.39, and below the 200-day MA of 95.42, indicating a bearish trend. The MACD of -4.04 indicates Positive momentum. The RSI at 19.40 is Positive, neither overbought nor oversold. The STOCH value of 4.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:SYNT.

Synthomer Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JMAT	76 Outperform	£3.55B	9.97	15.96%	3.61%	-9.10%	239.75%
CRDA	70 Outperform	£3.91B	27.92	6.17%	3.41%	2.36%	-13.99%
VCT	69 Neutral	£555.78M	18.71	6.65%	9.32%	4.75%	-3.29%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
ELM	57 Neutral	£918.66M	-16.22	3.37%	1.35%	-11.78%	-92.61%
ZTF	53 Neutral	£186.37M	265.28	0.60%	2.06%	15.56%	-92.94%
SYNT	40 Neutral	£81.78M	-0.98	-7.26%	―	-4.41%	2.29%

Synthomer Corporate Events

Synthomer Reports Resilient Q3 Performance Amid Market Challenges

Synthomer plc reported a resilient performance in Q3 2025 despite a challenging market environment, driven by its Adhesive Solutions division and strategic self-help initiatives. The company is focusing on cost efficiency, strategic transformation, and a broadened divestment program to strengthen its financial position and mitigate the impact of global trade tensions. Synthomer expects its 2025 EBITDA to be similar to 2024, with anticipated progress in earnings and cash generation in 2026 due to ongoing strategic actions and investments.

The most recent analyst rating on (GB:SYNT) stock is a Hold with a £54.00 price target. To see the full list of analyst forecasts on Synthomer stock, see the GB:SYNT Stock Forecast page.

Synthomer Appoints Peel Hunt as Joint Corporate Broker

Synthomer plc has appointed Peel Hunt LLP as a joint corporate broker alongside its existing broker, J.P. Morgan Cazenove. This strategic move aims to bolster Synthomer’s market positioning and enhance its investor relations efforts, potentially impacting its operations and stakeholder engagement positively.

The most recent analyst rating on (GB:SYNT) stock is a Hold with a £1.12 price target. To see the full list of analyst forecasts on Synthomer stock, see the GB:SYNT Stock Forecast page.

Synthomer Director Invests in Company Shares

Synthomer PLC announced that Uwe Halder, a Non-Executive Director, has purchased 25,000 ordinary shares of the company at a price of £0.637 per share, totaling £15,925. This transaction, conducted on the London Stock Exchange, reflects a significant investment by a key member of the company’s board, potentially indicating confidence in the company’s future performance and stability.

The most recent analyst rating on (GB:SYNT) stock is a Buy with a £275.00 price target. To see the full list of analyst forecasts on Synthomer stock, see the GB:SYNT Stock Forecast page.

Synthomer Director Increases Stake with Share Purchase

Synthomer plc announced that Jonathan Silver, a Non-Executive Director, has purchased 59,229 ordinary shares at a price of £0.655 each, totaling £38,795, on the London Stock Exchange. This transaction reflects a vote of confidence in the company’s prospects and could positively influence stakeholder perceptions regarding Synthomer’s market position and future growth potential.

The most recent analyst rating on (GB:SYNT) stock is a Buy with a £275.00 price target. To see the full list of analyst forecasts on Synthomer stock, see the GB:SYNT Stock Forecast page.

Synthomer CFO Acquires Shares, Signaling Confidence in Company

Synthomer PLC announced that Lily Liu, the company’s Chief Financial Officer, has purchased 20,000 ordinary shares at a price of £0.639 each, totaling £12,780, on the London Stock Exchange. This transaction reflects confidence in the company’s future prospects and may have implications for investor sentiment and market perception of Synthomer’s financial health.

The most recent analyst rating on (GB:SYNT) stock is a Buy with a £275.00 price target. To see the full list of analyst forecasts on Synthomer stock, see the GB:SYNT Stock Forecast page.

Synthomer Announces Board Changes Amid Strategic Succession Planning

Synthomer plc announced the resignation of independent Non-Executive Director Roberto Gualdoni, effective December 2025, as part of its board succession planning. The company has appointed two new independent Non-Executive Directors, Janet Ashdown and Jonathan Silver, effective July 2025, to strengthen its board. This change is part of Synthomer’s strategic efforts to enhance governance and support its long-term growth objectives.

The most recent analyst rating on (GB:SYNT) stock is a Buy with a £275.00 price target. To see the full list of analyst forecasts on Synthomer stock, see the GB:SYNT Stock Forecast page.

Synthomer Achieves Earnings Growth Amid Market Challenges

Synthomer reported continued earnings growth despite subdued market conditions for the first half of 2025. The company saw a 5.4% increase in EBITDA in constant currency, driven by self-help actions and strategic focus on speciality products. However, revenue decreased by 9.8% due to market volatility and tariff changes, impacting customer demand. The company completed the divestment of William Blythe and continued its strategic transformation by reducing manufacturing sites and expanding its divestment program. Synthomer remains focused on innovation and capital deployment, particularly in the Middle East and sustainable products, while navigating geopolitical and tariff-related uncertainties.

The most recent analyst rating on (GB:SYNT) stock is a Buy with a £275.00 price target. To see the full list of analyst forecasts on Synthomer stock, see the GB:SYNT Stock Forecast page.